Clinical Issues in Bipolar Depression
Consensus and Controversies Across the Spectrum of Patient Presentations
Meeting Slides
Guidelines
Diagnostic and Statistical Manual of Mental Disorders (Fifth edition). 2013.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Fifth edition). Arlington, VA: American Psychiatric Publishing
The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults (Third edition). 2016.
Arlington, VA: American Psychiatric Publishing.
2015 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults.
The University of South Florida, Florida Medicaid Drug Therapy Management Program for Behavioral Health.
Patient Resources
Depression and Bipolar Support Alliance
The Depression and Bipolar Support Alliance (DBSA) offers resources for patients, materials for clinicians, information on mental health research, as well as listings of patient support groups across the United States.
Clinical Assessment Tools
Clinically Useful Depression Outcome Scale with questions for the DSM-5 mixed features specifier (CUDOS-M)
This self-administered assessment scale detects the presence of mixed features in patients with major depressive disorder. With a rating scale of 0-4, where 0 is not at all true and 4 is almost always true, patients endorse the frequency of each symptom experienced during the prior week (Zimmerman M, et al. J Affect Disord. 2014;168:357-362).
Montgomery-Asberg Depression Rating Scale (MADRS)
This clinician-scored questionnaire assesses the severity of patient depression over the prior week on a scale of 0-6, where 0 denotes no symptoms and 6 indicates the most severe symptoms (Montgomery SA, Asberg M. Brit J Psychiatry. 1979;134:382-389).
The Bipolarity Index
This clinician-rated scale aims to provide diagnostic confidence when evaluating a patient with suspected bipolar disorder. Five sections evaluating the 5 illness dimensions are each scored from 0-20, with a final score ≥50 indicative of bipolar disorder (Sachs GS. Acta Psychiatr Scand. 2004;422(suppl):S7-S17; Aiken CB, et al. J Affect Disord. 2015;177:59-64).
The Mood Disorder Questionnaire (MDQ)
This self-administered assessment scale is intended to help clinicians screen patients for bipolar disorder. The 5-question evaluation can be completed in less than 5 minutes and provides important insight into diagnosis and treatment. A positive screen is noted if a patient answers YES to ≥7 out of 13 items in question 1, YES to question 2, and MODERATE or SERIOUS to question 3 (Hirschfeld RMA. Prim Care Companion J Clin Psychiatry. 2002;4(1):9-11).
Young Mania Rating Scale (YMRS)
This clinician-guided assessment is intended to identify the severity of patient abnormalities. The 11-statement assessment is used to describe the patient’s symptoms over the prior week through scoring on a 0-4 scale, where 0 is absence of symptoms (feeling normal) and 4 indicates the most severe symptoms (Young RC, et al. Br J Psychiatry. 1978;133(5):429-435).
Suggested Readings
Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association.
Goldstein BI, et al. Circulation. 2015;132(10):965-986. 2015;8(4):206-220
Mixed specifier for bipolar mania and depression: highlights of DSM-5 changes and implications for diagnosis and treatment in primary care.
Hu J, et al. Prim Care Companion CNS Disord. 2014;16(2).
The prevalence and illness characteristics of DSM-5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project.
McIntyre RS, et al. J Affect Disord. 2015;172:259-264.
Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
McIntyre RS, et al. J Clin Psychiatry. 2015;76(4):398-405.
Mixed depression in bipolar disorder: prevalence rate and clinical correlates during naturalistic follow-up in the Stanley Bipolar Network.
Miller S, et al. Am J Psychiatry. 2016; Apr 15. [Epub ahead of print].
A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.
Patkar A, et al. PLoS One. 2012;7(4):e34757.
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Perlis RH, et al. Am J Psychiatry. 2006;163(2):217-224.0
Mixed features in patients with a major depressive episode: the BRIDGE-II-MIX study.
Perugi G, et al. J Clin Psychiatry. 2015;76(3):e351-e358.
Factors related to suicidal behavior in patients with bipolar disorder: the effect of mixed features on suicidality.
Seo HJ, et al. Gen Hosp Psychiatry. 2016;39:91-96.
Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features.
Tohen M, et al. J Affect Disord. 2014;164:57-62.
Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity.
Zimmermann P, et al. Arch Gen Psychiatry. 2009;66(12):1341-1352.
Relevant Resources
Improved Diagnostic and Management Strategies
Overcoming Diagnostic Challenges, Targeting Remission, and Optimizing Cardiometabolic Health
New Approaches to Optimizing Patient Outcomes
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Accelerating Diagnosis, Achieving Remission, and Encouraging Adherence
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Managing Patients Across the Disease Spectrum
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices for Emergency Care
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCP’s Role in Timely Recognition and Referral
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Improving Patient Outcomes Through Shared Clinical Decision Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Finding the Way Forward
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
